Embargo will be lifted by Asco on abstract title and time of presentation on April 28, 2021.
Oral Presentation Details:
Title: "COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies"
Abstract: 2504
Session: Developmental Therapeutics—Immunotherapy
Date and Time: June 7, 202, 3:00 PM – 6:00 PM EDT
The abstract will be made available by ASCO on May 19, 2021, at 5:00 PM EDT on ASCO.org.
The presentation will be made available on Compugen's website at www.cgen.com following the conclusion of the presentation.